Clinical detection of silicosis is currently dependent on radiological abnormalities, a late manifestation of disease. A need for markers of prediction and early detection of pneumoconiosis is imperative for the early evaluation of dust allaying strategies. Understanding of the underlying mechanisms of the etiology of silicosis was instrumental in proposing numerous biomarkers that have been evaluated to assess effects following exposure to crystalline silica dust. Human validation studies have substantiated some of these proposed biomarkers and have argued in favour of their use as biomarkers for crystalline silica-induced pneumoconiosis. A number of 'ideal' biological markers of effect were identified through literature review, viz. TNF, IL-8 and ROS measurement by chemiluminescence (monocyte release), CC16, 8-isoprostanes, total antioxidant levels measured by TEAC, glutathione, glutathione peroxidase, glutathione S-transferase, and PDGF (serum). These identified biomarkers were then evaluated in South African gold miners exposed to silica with and without clinical evidence of silicosis and in control group of men with no silica dust exposure. Results showed that three out of the 10 biomarkers investigated were significantly affected by exposure to silica dust, independently of any effects due to HIV infection, ARV treatment, smoking or age, to an extent that would enable them to be used as biomarkers of early effects due to exposure to crystalline silica. Financial support from Mine Health and Safety Council and permission from Harmony gold mines to recruit volunteer subjects from their mine workforce are gratefully acknowledged.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.